Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tuberculosis drug discovery in the CRISPR era

19 Sept 2019

Abstract excerpt

Stewart Cole and colleagues determined the complete genome sequence of Mycobacterium tuberculosis (Mtb), the etiological agent of tuberculosis (TB), in 1998 [1].This was a landmark achievement that heralded a new age in TB drug discovery.With the genome sequence in hand, drug discoverers suddenly had thousands of new potential targets to explore.But the excitement has since faded [2].It is unquestioned that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31536613
DOI: 10.1371/journal.ppat.1007975

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tuberculosis drug discovery in the CRISPR eraPMID 31536613Read ↗

CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosisSemantic proximity Read ↗

Direct detection from sputum for drug-resistant Mycobacterium tuberculosis using a CRISPR-Cas14a-based approachSemantic proximity Read ↗

Reprogramming Mycobacterium Tuberculosis CRISPR System for Gene Editing and Genome-Wide RNA Interference ScreeningSemantic proximity Read ↗

A chemical-genetic map of the pathways controlling drug potency in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges.Semantic proximity Read ↗

Intracellular Drug Targets In Mycobacterium Tuberculosis Revealed By A Chemo-Genetic ApproachSemantic proximity Read ↗

Outlook for CRISPR-based tuberculosis assays now in their infancySemantic proximity Read ↗

Tuberculosis drug discovery in the post‐post‐genomic eraSemantic proximity Read ↗

Pangenome-wide association study reveals selective absence of CRISPR genes (Rv2816c-19c) in drug-resistant<i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

Reprogramming the endogenous type III-A CRISPR-Cas system for genome editing, RNA interference and CRISPRi screening in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

The future of CRISPR in Mycobacterium tuberculosis infectionSemantic proximity Read ↗

Pathogen-based precision medicine for drug-resistant tuberculosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.